Dexoligo Therapeutics

What Dexoligo Therapeutics does

Dexoligo Therapeutics is an Israel-based biotechnology company founded in 2021 as a wholly-owned subsidiary of Dexcel Pharma that develops RNA oligonucleotide therapeutics, specifically siRNA (small interfering RNA) drugs, for diseases of high unmet medical need. Its core technical approach pairs validated GalNAc (N-Acetylgalactosamine) conjugation chemistry, which enables selective uptake of conjugated oligonucleotides by hepatocytes via asialoglycoprotein receptors, with RNA interference mediated through the RISC complex to achieve durable, sequence-specific silencing of disease-driving genes following subcutaneous administration. The company's disclosed pipeline comprises DXO-1801, a first-in-class GalNAc-siRNA targeting the hepcidin regulatory pathway for Anemia of Inflammation and currently in IND/CTA-enabling studies; DXO-1803, a GalNAc-siRNA for Metabolic Syndrome at preclinical proof-of-concept stage; DXO-1804, a liver-directed siRNA for CKD-associated Anemia at discovery stage; and an undisclosed extrahepatic delivery platform intended to extend siRNA targeting beyond the liver.

The company operates with a lean, specialist organization of approximately 11–50 employees based at 154 Menakhem Begin Road in Tel Aviv, structured around functional heads covering CMC, Discovery, Development, Computational Biology, Translational Sciences, ADME/PK and Clinical Pharmacology, Laboratory Operations, and Business Development. Dexoligo is pre-revenue and pre-commercial; it has no marketed products, no disclosed licensing or co-development transactions, and no external institutional funding rounds in the source data, with capitalization appearing to flow from its strategic parent Dexcel Pharma. Near-term value creation is expected through clinical progression of DXO-1801 toward first-in-human studies and subsequent licensing or co-development deals with major pharmaceutical partners for global commercialization, with credibility currently being built through peer-reviewed publication in Blood (November 2025) and presentations at ASH 2025, the 2026 Israel Nucleic Acid Therapeutics Meeting, and EHA 2026.

Name

Dexoligo Therapeutics

Legal name

Dexoligo Therapeutics

Website

https://dexoligo.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Dexoligo Therapeutics is an Israel-based, Dexcel Pharma–owned biotechnology company developing GalNAc-conjugated siRNA therapeutics for anemia of inflammation, metabolic syndrome, and CKD-associated anemia, with DXO-1801 advancing into IND/CTA-enabling studies.

Ownership category

akta.pro rank

Product category

RNA Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

Keywords

• RNA therapeutics
• SiRNA drugs
• Oligonucleotide therapeutics
• GalNAc delivery
• Gene silencing

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. RNA Therapeutic Development and Commercialization: Pre-revenue biotech company developing a pipeline of RNA oligonucleotide therapeutics. Revenue generation expected through eventual commercialization of drug candidates, licensing agreements, and/or co-development partnerships with major pharmaceutical companies upon successful clinical and regulatory milestones.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Dexoligo Therapeutics develops RNA oligonucleotide therapeutics, specifically GalNAc-conjugated siRNA drugs, targeting liver and extrahepatic tissues. The company has a pipeline of three disclosed candidates — DXO-1801 (anemia of inflammation), DXO-1803 (metabolic syndrome), and DXO-1804 (CKD-associated anemia) — plus an undisclosed extrahepatic delivery platform, all built on RNAi gene-silencing technology.

Product overview

Dexoligo Therapeutics is a biopharmaceutical company developing RNA oligonucleotide therapeutics, specifically siRNA (small interfering RNA) drugs. The company's product portfolio consists of four pipeline candidates: DXO-1801 (GalNAc-conjugated liver-targeted siRNA for Anemia of Inflammation, in IND/CTA enabling studies), DXO-1803 (GalNAc-conjugated liver-targeted siRNA for Metabolic Syndrome, in preclinical stage), DXO-1804 (GalNAc-conjugated liver-directed siRNA for CKD-associated Anemia, in discovery), and an undisclosed novel delivery platform for extrahepatic siRNA targeting. The therapeutic approach leverages validated GalNAc delivery technology for hepatocyte-specific uptake and RNAi mechanism for gene silencing. Founded in 2021 as a subsidiary of Dexcel Pharma.

Differentiator

Problem solved

Functional benefit

Products and services

• DXO-1801

Quantifiable outcome

• DXO-1801 demonstrated attenuation of inflammation-driven iron restriction and enhanced erythropoiesis in non-human primates (published in Blood, November 2025)
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Viridian Therapeutics: siRNA therapeutics company (acquired by Takeda in 2024) developing GalNAc-conjugated programs. Closely comparable in platform approach and target organ focus.
• Alnylam Pharmaceuticals: Pioneer and market leader in GalNAc-conjugated siRNA therapeutics, with multiple approved products (Onpattro, Givlaari, Oxlumo, Amvuttra) and a broad clinical pipeline. Direct competitor in the same siRNA modality and liver-targeted delivery approach.
• Wave Life Sciences: Oligonucleotide therapeutics company developing RNA-targeting modalities including siRNA-adjacent approaches. Comparable in oligonucleotide chemistry and target disease focus.
• Arrowhead Pharmaceuticals: Develops GalNAc-conjugated siRNA therapeutics (TRiM platform) with multiple clinical-stage programs across hepatic and extrahepatic targets. Closely comparable in delivery chemistry and pipeline breadth.
• Dicerna Pharmaceuticals: GalNAc-siRNA platform company (acquired by Novo Nordisk in 2021) with clinical programs in hepatic diseases. Direct modality competitor before acquisition.
• Silence Therapeutics: Clinical-stage siRNA company using GalNAc delivery to silence disease-causing genes in the liver. Comparable modality, target organ focus, and pipeline maturity stage.

Emerging players

• Ascidian Therapeutics: Early-stage RNA editing therapeutics company targeting genetic diseases. Comparable as an emerging RNA-modality biotech with strong scientific backing.
• City Therapeutics: Newly formed siRNA therapeutics company founded by key Alnylam alumni to advance next-generation RNAi medicines. Comparable as an emerging siRNA platform play.
• Sirnaomics: Clinical-stage siRNA therapeutics company developing both GalNAc-conjugated and nanoparticle-formulated RNAi candidates. Comparable in siRNA modality with a more delivery-diverse approach.

Broad incumbents

• Ionis Pharmaceuticals: Established RNA-targeted therapeutics leader focused on antisense oligonucleotides (ASOs) rather than siRNA. Comparable in RNA therapeutic modality, target disease breadth, and BD/licensing model.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dexoligo-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dexoligo Therapeutics